EICHORPublic-registry site landscape for NCT04129775, “OTO-413 in Subjects With Speech-in-Noise Hearing Impairment”, a Sensorineural Hearing Loss study sponsored by Otonomy, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04129775 (registry record) |
| Study title | OTO-413 in Subjects With Speech-in-Noise Hearing Impairment |
| Official title | A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment |
| Sponsor | Otonomy, Inc. |
| Condition(s) | Sensorineural Hearing Loss |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 8 |
| Intervention(s) | OTO-413, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04129775.
Eichor generates a preliminary site-risk snapshot for NCT04129775 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
